Tilray Brands (TLRY) is up ~7% in after-hours trading Thursday after posting fiscal 2026 Q2 financial results that beat on the top line, including achieving record quarterly revenue.
The Canadian cannabis LP’s success in the corner was driven by an overall 3% increase in cannabis revenue. The company saw a 36% year-over-year increase in international cannabis sales.
Beverage sales were a disappointment as they declined to $50.1M from $63.1M in the year-ago period.
Overall revenue of $217.51M was a 3% increase compared to FY25 Q2.
Adjusted net loss per share in Q2 improved to $(0.02) compared to $(0.03) in the year-ago period.
Tilray also reaffirmed its FY26 adjusted EBITDA guidance.
The company also noted that the expected rescheduling of marijuana in the US as recently directed by President Trump could provide an opportunity for medical marijuana expansion.
